Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Soligenix has specialized expertise in the development of orphan and unmet medical need indications – including the regulatory nuances (Orphan Drug designation, Fast Track designation, use of adaptive trial designs etc.) and clinical execution (specialized recruitment approaches, direct site interactions etc.). Soligenix directly conducts all of its Phase 2 and 3 clinical studies, being in personal contact with the sites and principal investigators, ensuring the highest data quality while streamlining timelines and budgets.
By working in indications where treatment is lacking and populations are specialized, Soligenix has an outsized impact on patient outcomes and quality of life.
The regulatory commonalities between all indications in rare disease/unmet medical need means that Soligenix expertise can be impactful across a variety of diseases: